Delving into the Latest Updates on CyTuVax BV with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Skin and Musculoskeletal Diseases

Therapeutic vaccine

Personalized antigen vaccine

mRNA vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Therapeutic vaccine	2
Personalized antigen vaccine	1
mRNA vaccine	1

In the current study, the investigators study the efficacy of the HBAI20 vaccine to induce seroprotection in registered non-responders (adults who were previously vaccinated with the HBVaxPro-10μg but did not achieve seroprotection). The study will further assess the safety of the HBAI20 vaccine in comparison with HBVaxPro-10μg.

Start Date11 Oct 2017

Sponsor / Collaborator

Maastricht UMC+

[+1]

NL-OMON41999

/ CompletedNot Applicable

Safety and immunogenicity of HBAI20 adjuvanted Hepatitis B vaccine in naive adults and non-responders - HBAI20

Start Date11 Oct 2017

Sponsor / Collaborator

CyTuVax BV

NCT02540538

/ CompletedPhase 1IIT

Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

The purpose of this study is to determine whether the HBAI20 vaccine is safe and more immunogenic than the HBVaxPro-10µg in people who have never been vaccinated with a hepatitis B vaccine and in people who have been vaccinated 6 times with hepatitis B vaccine but do not have a protective anti hepatitis B antibody titer.

Start Date01 Sep 2015

Sponsor / Collaborator

Maastricht UMC+

[+1]

100 Clinical Results associated with CyTuVax BV

Login to view more data

0 Patents (Medical) associated with CyTuVax BV

Login to view more data

100 Deals associated with CyTuVax BV

Login to view more data

100 Translational Medicine associated with CyTuVax BV

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Other

Login to view more data